In 2025’s rapidly evolving environment, prioritizing optimal health and peak performance is more critical than ever. As more ...

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.

I missed Creative Assembly's final post of 2024, but it does make it sound very much like we're getting a Total War: Warhammer 40,000 announcement soon.

Scientists at La Jolla Institute for Immunology (LJI) have discovered how a mutated gene kicks off a dangerous chain of ...